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A B S T R A C T
Background
Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1)
receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release
of insulin. GLP-1 receptors have been found in the brain. Insulin signalling in the brain plays a key role in neuronal metabolism and repair
and in synaptic eEicacy, but insulin signalling is desensitised in the brain of people with PD. Researchers are exploring the neuroprotective
eEects of GLP-1 receptor agonists in neurodegenerative disorders such as PD.
Objectives
To evaluate the eEectiveness and safety of GLP-1 receptor agonists for Parkinson's disease.
Search methods
We searched the Cochrane Movement Disorders Group trials register; the Cochrane Central Register of Controlled Trials (CENTRAL), in the
Cochrane Library; and Ovid MEDLINE and Embase. We also searched clinical trials registries, and we handsearched conference abstracts.
The most recent search was run on 25 June 2020.
Selection criteria
We included randomised controlled trials (RCTs) of adults with PD that compared GLP-1 receptor agonists with conventional PD treatment,
placebo, or no treatment.
Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We rated the quality of evidence
using GRADE. We resolved discrepancies between the two data extractors by consultation with a third review author.
Main results
Through our searches, we retrieved 99 unique records, of which two met our inclusion criteria. One double-blind study of exenatide versus
placebo randomised 62 participants, who self-administered exenatide or placebo for 48 weeks and were followed up at 60 weeks aKer
a 12-week washout. One single-blind study of exenatide versus no additional treatment randomised 45 participants; participants in the
intervention group self-administered exenatide for 12 months, and all participants were followed up at 14 months and 24 months following
absence of exenatide for 2 months and 12 months, respectively. These trials had low risk of bias, except risk of performance bias was high
for Aviles-Olmos 2013.
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Exenatide versus placebo
Primary outcomes
We found low-certainty evidence suggesting that exenatide improves motor impairment as assessed by the Movement Disorder Society-
Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in the oE-medication state (mean diEerence (MD) -3.10, 95% confidence
interval (CI) -6.11 to -0.09). The diEerence in scores was slightly greater when scores were adjusted for baseline severity of the condition
(as reported by study authors) (MD -3.5, 95% CI -6.7 to -0.3), exceeding the minimum clinically important diEerence (MCID).
We found low-certainty evidence suggesting that exenatide has little or no eEect on health-related quality of life (HRQoL) as assessed by
the Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI) (MD -1.80, 95% CI -6.95 to 3.35), the EuroQol scale measuring health
status in five dimensions (EQ5D) (MD 0.07, 95% CI -0.03 to 0.16), or the EQ5D visual analogue scale (VAS) (MD 5.00, 95% CI -3.42 to 13.42).
Eight serious adverse events (SAEs) were recorded, but all were considered unrelated to the intervention. Low-certainty evidence suggests
that exenatide has little or no eEect on weight loss (risk ratio (RR) 1.25, 95% CI 0.89 to 1.76).
Exenatide versus no treatment
Primary outcomes at 14 months
We found very low-certainty evidence suggesting that exenatide improves motor impairment as assessed by MDS-UPDRS Part III oE
medication (MD -4.50, 95% CI -8.64 to -0.36), exceeding the MCID. We are uncertain whether exenatide improves HRQoL as assessed by the
PDQ-39 SI (MD 3.50, 95% CI -2.75 to 9.75; very low-quality evidence). We found very low-certainty evidence suggesting that exenatide has
little or no eEect on the number of SAEs (RR 1.60, 95% 0.40 to 6.32). We found very low-certainty evidence suggesting that exenatide may
lead to weight loss (MD -2.40 kg, 95% CI -4.56 to -0.24).
Primary outcomes at 24 months
We found evidence as reported by study authors to suggest that exenatide improves motor impairment as measured by MDS-UPDRS Part
III oE medication (MD 5.6 points, 95% CI 2.2 to 9.0). Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may
not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8).
Authors' conclusions
Low- or very low-certainty evidence suggests that exenatide may improve motor impairment for people with PD. The diEerence in motor
impairment observed between groups may persist for some time following cessation of exenatide. This raises the possibility that exenatide
may have a disease-modifying eEect. SAEs were unlikely to be related to treatment. The eEectiveness of exenatide for improving HRQoL,
non-motor outcomes, ADLs, and psychological outcomes is unclear. Ongoing studies are assessing other GLP-1 receptor agonists.
P L A I N   L A N G U A G E   S U M M A R Y
Can exenatide, a diabetes drug, be used to treat Parkinson's disease?
Review question
To evaluate the eEectiveness and safety of GLP-1 receptor agonists for Parkinson's disease.
Background
People with Parkinson's disease (PD) have problems with movement, such as slow movement and shaking at rest. They may also have other
problems such as depression, diEiculty swallowing, and gastrointestinal dysfunction. Glucagon-like peptide-1 (GLP-1) receptor agonists
are used for treatment of type 2 diabetes. They work by stimulating GLP-1 receptors in the pancreas, which causes the release of insulin.
GLP-1 receptors have also been found in the brain. Neurones in the brain send signals to and from the brain and the rest of the body. Insulin
signalling in the brain is important for keeping neurones healthy, but it has been shown that insulin signalling does not work well in the
brain of people with PD. Researchers are interested in finding out about the protective eEects of GLP-1 receptor agonists on neurones, and
how these agonists might help people with disease aEecting the brain, such as PD.
Study characteristics
We found two studies that provided data for a total of 104 patients (following dropout of three patients). One study compared exenatide
(a GLP-1 receptor agonist) versus placebo (a pretend medicine), and the other study compared exenatide versus no treatment (other than
the usual treatment that people received). Evidence is current to June 2020.
Key results
We found low-certainty evidence suggesting that people who took exenatide had better improvement in motor symptoms than people who
took placebo. Movement was measured 12 weeks aKer patients had stopped taking exenatide. We found low-certainty evidence suggesting
GLP-1 receptor agonists for Parkinson's disease (Review)
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that for people taking exenatide, there may be little or no diEerence in health-related quality of life (HRQoL). Six serious adverse events
(SAEs) were seen in people taking exenatide and two in people taking placebo, but all were considered by the study authors to be not
related to the drug.
We found very low-certainty evidence suggesting that people who took exenatide had better improvement in motor symptoms than people
who received no treatment other than their usual care. Movement was measured two months aKer patients stopped taking exenatide. We
found very low-certainty evidence suggesting that exenatide compared to no treatment had little or no eEect on HRQoL, and we found
very low-certainty evidence suggesting little or no diEerence in the number of SAEs among people taking exenatide.
Quality of evidence
The quality of evidence was low or very low. In one study, people not taking exenatide received their usual treatment only; thus, people in
the study knew whether they were given extra treatment, and this may have changed the study results.
Conclusions
We are uncertain whether exenatide may improve motor symptoms for people with PD. The improvement in symptoms found in two small
studies persisted for several weeks aKer people stopped taking the drug. This might mean that the drug has modified the disease process in
some way. More studies with more people are needed so that we can be more sure whether GLP-1 receptor agonists do help people with PD.
GLP-1 receptor agonists for Parkinson's disease (Review)






































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   GLP-1 receptor agonists compared to placebo for adults with Parkinson's disease
GLP-1 receptor agonists compared to placebo for adults with Parkinson's disease
Patient or population: adults with Parkinson's disease
Setting: research institutes, tertiary care facilities


























Assessed with MDS-UPDRS Part III
Follow-up: 60 weeks
MDS-UPDRS Part III: 33 scores based on 18 items due to leK,
right, and other body distributions, scored as 0 normal, 1 slight,
2 mild, 3 moderate, 4 severe. Scale from 0 to 132. MCID of -3.25
















GLP-1 receptor agonists pro-
duced a significant mean be-
tween-group reduction in motor
impairment score. MD of -3.1 not
≥ MCID of -3.25 for improvement
HRQoL
Assessed with PDQ-39 SI
Follow-up: 60 weeks
PDQ-39 SI: 39 items, 5-point ordinal scoring system 0 = never,
1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Lower















No significant difference in mean
between-group quality of life
scores. MD of -1.8 not ≥ MCID of
-4.72 for improvement
Serious adverse events
Assessed with number of participants with an SAE
Follow-up: 48 weeks
The included study did not report the number of participants with an SAE. The study reported the num-
































































































































Adverse events - weight loss
Assessed with number of participants who lost weight
Follow-up: 48 weeks










No significant difference in
weight loss between groups re-
ceiving exenatide or placebo
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; GLP-1: glucagon-like peptide-1; HRQoL: health-related quality of life; MCID: minimal clinically important difference; MD: mean difference; MDS-UP-
DRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale; PDQ-39 SI: Parkinson's Disease Questionnaire Summary Index; RA: receptor agonist; RCT: ran-
domised controlled trial; RR: risk ratio; SAE: serious adverse event.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded for indirectness as the intervention was only one example of an RA.
bWe downgraded for imprecision due to a small sample size. CI excludes no eEect and fails to exclude appreciable benefit (MCID = -3.25 for improvement).
cWe downgraded for imprecision due to a small sample size. CI includes no eEect and fails to exclude appreciable benefit (MCID = -4.72 for improvement).
dWe downgraded for imprecision due to a small sample size. CI includes no eEect and fails to exclude appreciable harm.
 
 
Summary of findings 2.   GLP-1 receptor agonists compared to no treatment for adults with Parkinson's disease
GLP-1 receptor agonists compared to no treatment for adults with Parkinson's disease
Patient or population: adults with Parkinson's disease
Setting: research institutes, tertiary care facilities
Intervention: GLP-1 receptor agonists
Comparison: no treatment
Anticipated absolute effects* (95% CI)Outcomes























Mean PD motor im-
pairment; change from
baseline in MDS-UP-
DRS Part III was 2.8
MD 4.5 lower (8.64







Exenatide produced a significant mean be-
tween-group reduction in motor impairment score.






































































































































PDQ-39 SI was 2.3
MD 3.5 higher (2.75 







No significant difference in mean between-group
quality of 
life scores. MCID = -4.72 for improvement and 4.22
for worsening
Serious adverse events.
Assessed with number of par-
ticipants with an SAE
Follow-up: 14 months










No significant difference in the number of serious
adverse 
events reported between groups receiving exe-
natide or placebo
Adverse events - weight loss
Assessed with mean weight loss
Follow-up: 12 months
Mean weight loss;
change from baseline 
in kg was -3.2
MD 2.4 kg lower







Participants in the exenatide group lost significant-
ly more weight than participants in the no treat-
ment group
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; GLP-1: glucagon-like peptide-1; HRQoL: health-related quality of life; MCID: minimal clinically important difference; MD: mean difference; MDS-UP-
DRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale; PD: Parkinson's disease; PDQ-39 SI: Parkinson's Disease Questionnaire Summary Index; RA: re-
ceptor agonist; RCT: randomised controlled trial; RR: risk ratio; SAE: serious adverse event.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded for study limitations of high risk of performance bias.
bWe downgraded for indirectness as the intervention was only one example of an RA.
cWe downgraded for imprecision due to a small sample. CI excludes no eEect and fails to exclude appreciable benefit (MCID = -3.25 for improvement).
dWe downgraded for imprecision due to a small sample size. CI fails to exclude no eEect and appreciable harm (MCID = 4.22 for worsening).
eWe downgraded for imprecision due to a small sample size. CI includes no eEect and fails to exclude appreciable harm or benefit.
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B A C K G R O U N D
Description of the condition
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder aKer Alzheimer’s disease (AD),
aEecting approximately 0.5% of the population over 60 years of age
in industrialised countries (Pringhseim 2014). PD is caused by loss
of dopamine-producing nerve cells in the part of the brain called
the substantia nigra. Dopamine functions as a neurotransmitter
and plays a key role in motor control. It is not known what causes
the loss of these dopamine-producing nerve cells.
PD is a long-term, progressive disorder that causes significant
disability. Symptoms generally develop slowly, typically over 10
to 15 years. PD is characterised by motor features (problems with
movement) that include slow movement, shaking at rest, muscular
rigidity, and postural instability (Kalia 2015), along with a variety of
non-motor features that include loss of the sense of smell and sleep
and psychiatric dysfunction, including depression, anxiety, and
dementia. As the disease progresses and treatment-resistant motor
and non-motor features dominate, falls, freezing gait, choking,
urinary incontinence, and dementia are common (Hely 2005; Hely
2008).
PD shows increasing incidence with age and is more common
among men than women (Hirsch 2016). Risk factors for PD include
exposure to pesticides and other environmental chemicals (oKen
experienced by agricultural workers), high consumption of dairy
products, a diagnosis of melanoma, and traumatic brain injury
(Ascherio 2016; de Lau 2006). Protective factors include use of
tobacco; consumption of coEee, caEeine, and tea; higher plasma
concentrations of urates (salts of uric acid); physical activity; and
use of non-steroidal anti-inflammatory drugs (Ascherio 2016).
At present, no eEective disease-modifying or neuroprotective
interventions are known; current therapies for PD are provided
to treat symptoms only. Available therapies include levodopa,
which is converted in the brain (as well as in the periphery)
to dopamine, and dopamine receptor agonists, which stimulate
dopamine receptors.
Typically, PD is defined pathologically by prominent loss of
dopaminergic neurons and the presence in the brain of Lewy
bodies containing α-synuclein. It is increasingly recognised that
the neurodegenerative process in PD is complex and multi-factorial
and is likely to involve mitochondrial dysfunction and oxidative
stress (Abou-Sleiman 2006), inflammation (Collins 2012), blood-
brain barrier dysfunction (Gray 2015), and neurovascular changes
(Al-Bachari 2017). Such factors are likely to have treatment and
prognostic implications. Vascular comorbidity (including prior
stroke, transient ischaemic attack (TIA), or more than two vascular
risk factors), for instance, has been found to be significantly
associated with cognitive and gait impairment in early PD (Malek
2016).
Description of the intervention
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of
drugs that are licensed for treatment of type 2 diabetes (Baggio
2007; Campbell 2013; Doyle 2003; Holst 2004). An agonist acts by
binding to a receptor (a protein molecule that is the target for the
drug), which causes some form of cellular response (Pleuvry 2004).
For people with type 2 diabetes, GLP-1 receptor agonists work by
stimulating GLP-1 receptors in the pancreas, which triggers the
release of insulin. However, GLP-1 receptors have also been found
in the brain; thus GLP-1 receptor agonists may also play a role in the
treatment of PD. Insulin signalling in the brain plays a key role in
neuronal metabolism and repair and in synaptic eEicacy (Freiherr
2013; Ghasemi 2013; van der Heide 2006). Insulin activates growth
factor receptors on neurones that control energy utilisation, cell
repair, mitochondrial function, synapse growth, and functionality.
Several classic second messenger cell signalling pathways are
activated while apoptotic (programmed cell death) cell signalling is
inhibited (Hölscher 2014). It has been shown that insulin signalling
is desensitised in the brain of people with PD (Aviles-Olmos 2013a;
Moroo 1994; Morris 2011), which may explain why type 2 diabetes
has been identified as a risk factor for development of PD (Hu 2007;
Schernhammer 2011; Sun 2012; Wahlqvist 2012). GLP-1 receptor
agonists are administered by subcutaneous injection.
How the intervention might work
GLP-1 activates the same key growth factor cell signalling
cascades as insulin, and therefore compensates for loss of insulin
signalling (Jalewa 2016). Protease-resistant analogues of GLP-1
have shown neuroprotective eEects in animal models of AD
(Bomfim 2012; Li 2010; McClean 2011), and they have been
found to re-sensitise insulin signalling in the brain (Long-Smith
2013). Furthermore, previous studies found that GLP-1 receptor
agonists have neuroprotective eEects in animal models of PD. The
GLP-1 mimetic (molecule resembling GLP-1), exendin-4, protected
motor activity and dopamine levels in the striatum, and reduced
chronic inflammation and oxidative stress (Harkavyi 2008; Li
2009; Liu 2015a; Zhang 2015). In the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model of PD, GLP-1 mimetics
protected the brain from aspects of MPTP-induced pathology,
such as motor impairment, increased α-synuclein levels, chronic
inflammation in the brain, loss of dopaminergic neurons, oxidative
stress, and growth factor expression (Ji 2016; Li 2016; Liu 2015a;
Liu 2015b; Zhang 2015). The GLP-1 mimetics liraglutide and
lixisenatide are more eEective than the first-generation drug
exenatide. The newer GLP-1 mimetics improve motor co-ordination
and activity, and both drugs rescue the expression of tyrosine
hydroxylase, a key enzyme in dopamine synthesis (Liu 2015a).
A challenge for clinical trials for neurodegenerative diseases such
as PD is to diEerentiate between the disease-modifying eEects
and the symptomatic eEects of any therapeutic agent. Scales
used in clinical assessment of PD to measure changes in, for
example, motor impairment or quality of life are unable to
distinguish between symptomatic and disease-modifying eEects of
a treatment; thus, for any novel potential treatment to demonstrate
disease modification, there needs to be evidence that the drug,
when administered for a period of time, stops or slows disease
progression. This can be demonstrated in a clinical trial by
the absence of deterioration in clinical outcome measures by
comparison with a control or placebo group. Inclusion of a
washout period in clinical trial design or long-term follow-up
helps to confirm that any diEerences in clinical outcome measures
observed between treatment groups are indeed evidence of
disease modification rather than symptomatic eEects (McGhee
2013). Changes in relevant biomarkers, such as presynaptic striatal
dopamine transporter (DAT) binding as assessed by [123I]FP-
CIT single-photon emission computed tomography (DaTSCAN)
examination, would provide additional evidence of disease
GLP-1 receptor agonists for Parkinson's disease (Review)
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modification. In addition, confounders may influence therapeutic
eEects. For example, although evidence suggests that GLP-1 can
cause weight loss (Vilsbøll 2012), it is known that the amount of
levodopa and its maximum concentration in plasma are negatively
correlated with body weight (Müller 2000), and consequently
weight loss can lead to increased eEectiveness of levodopa; thus
awareness of potential changes in weight loss due to GLP-1 and
subsequent therapeutic eEects on PD is essential in the study of
GLP-1 receptor agonists.
Why it is important to do this review
Recent advances in our understanding of the neuroprotective
eEects of incretin-based therapies, including GLP-1 receptor
agonists, mean that there is considerable interest in their potential
utility as re-purposed treatment for several neurodegenerative
disorders, including PD. People with PD treated with exenatide in
an open-label clinical trial showed clinical benefit (Aviles-Olmos
2013b), with subsequent evidence of significant improvement in
motor features 12 months aKer stopping exenatide (Aviles-Olmos
2014). Similarly, a recent double-blind clinical trial of people with
PD found that those treated with exenatide showed improved
motor features 60 weeks aKer coming oE the medication, while
motor features for those on placebo had worsened (Athauda 2017).
It is therefore timely to undertake this review of GLP-1 receptor
agonists for PD, as this will provide a summary of the current state
of the evidence and a platform for updating the evidence base as
results of future studies become available.
O B J E C T I V E S
To evaluate the eEectiveness and safety of GLP-1 receptor agonists
for Parkinson's disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished, parallel-designed,
randomised controlled trials (RCTs). We excluded cross-over trials
due to uncertainty about whether this type of study design is
appropriate for studying people with PD (Higgins 2011).
Types of participants
We included trials in any setting with a study population of adults
(i.e. ≥ 18 years of age) with a clinical diagnosis made by any
physician, specialist, or otherwise of PD according to the UK
Parkinson’s Disease Society Brain Bank diagnostic criteria (Hughes
1992), or other equivalent clinical diagnostic criteria, or on the
basis of clinical neurological assessment. We included people at
all stages of the disease. Participants may have medical conditions
in addition to PD. We did not apply any restrictions based on the
number of participants recruited to trials nor on the number of
recruitment centres.
Types of interventions
We included studies that involved delivery of GLP-1 receptor
agonists with no restrictions on dosage or duration of treatment.
We included studies in which experimental and comparator groups
received an intervention (either active or inactive) in addition
to conventional treatment. We planned to assess the following
comparisons.
1. GLP-1 receptor agonists versus conventional PD treatment.
2. GLP-1 receptor agonists versus placebo intervention.
3. GLP-1 receptor agonists versus no treatment.
Types of outcome measures
Primary outcomes
1. PD motor impairment as measured by the Movement Disorder
Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
subscale Part III (Fahn 1987)
2. Health-related quality of life (HRQoL) as measured by a validated
scale such as:
a. Parkinson’s Disease Questionnaire (PDQ)-39 (Peto 1995), or
short form PDQ-8 (Jenkinson 1997);
b. Parkinson's Disease Quality of Life Questionnaire (PDQL) (de
Boer 1996); or
c. 36-Item Short Form Health Survey (SF-36) (Ware 1992)
3. Adverse events, including rapid weight loss (> 1.5 kg/week) (we
have defined adverse events as serious based on information
reported by individual trials)
Secondary outcomes
1. PD motor impairment as measured by a validated scale other
than UPDRS subscale Part III (Fahn 1987), such as the Unified
Dyskinesia Rating Scale (UDysRS) (Goetz 2008)
2. Non-motor outcomes as measured by validated scales including
UPDRS Part I (Fahn 1987), as well as the Non-Motor Symptoms
Questionnaire (NMSQuest) (Chaudhuri 2008)
3. Activities of daily living (ADLs) as measured by scales such as
UPDRS Part II (Fahn 1987), as well as Schwab and England
Activities of Daily Living (SEADL) (Schwab 1969)
4. Psychological outcomes such as dementia and depression as
measured by validated scales (e.g. the Mattis Dementia Rating
Scale (DRS) (Mattis 1976); the Montgomery-Åsberg Depression
Rating Scale (MADRS)) (Montgomery 1979)
These primary and secondary outcomes address key disease
aspects identified as important by patients and clinicians;
outcomes classified as related to participation, mobility, and motor
functioning were considered the most important (Hammarlund
2012), and these are assessed by UPDRS Parts I and III, respectively.
A minimal clinically important diEerence (MCID) for the motor
examination portion of the MDS-UPDRS is asymmetrical, with -3.25
points for detecting minimal but clinically important improvement,
and 4.63 points for observing minimal but clinically important
worsening (Horváth 2015). An estimate of a minimal clinically
important improvement on the PDQ-39 SI is -4.72, and an estimate
for worsening is +4.22 (Horváth 2017). As we were keen to
assess the neuroprotective eEects of GLP-1 receptor agonists, we
reported outcomes assessed two to three months post cessation of
treatment. Reporting one or more of the outcomes listed was not
an inclusion criterion for trials considered for this review.
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Search methods for identification of studies
Electronic searches
We searched the following databases from the date of inception to
June 2020 for relevant studies.
1. Cochrane Movement Disorders Group trials register.
2. Cochrane Central Register of Controlled Trials (CENTRAL), in the
Cochrane Library (Appendix 1).
3. MEDLINE (OVID) (1946 to present) (Appendix 2).
4. Embase (1974 to present) (Appendix 3).
Searching other resources
We searched the following clinical trials registers.
1. World Health Organization (WHO) Portal (covers
ClinicalTrials.gov; International Standard Randomized
Controlled Trials Number (ISRCTN); Australian and New Zealand
Clincal Trial Registry; Chinese Clinical Trial Register; India
Clinical Trials Registry; German Clinical Trials Register; Iranian
Registry of Clinical Trials; Sri Lanka Clinical Trials Registry; The
Netherlands National Trial Register): www.who.int/trialsearch.
We searched up to May 2019.
2. UK Clinical Trials Gateway: www.ukctg.nihr.ac.uk/default.aspx.
We searched up to June 2020.
We handsearched abstracts of the 16th to 21st International
Congresses of the Parkinson's Disease and Movement Disorders
conference (2012 to 2019) and meeting abstracts from the
Association of British Neurologists (2012 to 2017). As this
therapy is relatively new, we handsearched the more recent
conference proceedings. In June 2020 we searched the clinical
trials listed on the Journal of Parkinson's Disease website (https://
www.journalofparkinsonsdisease.com/). We also screened the
reference lists of included trials and review articles for potentially
eligible studies.
Data collection and analysis
Selection of studies
We merged the results of our searches and removed duplicates.
Two review authors (GD, JH) independently screened titles and
abstracts of studies identified by our search for potential inclusion
in the review. We searched for full-text reports of all potentially
relevant studies remaining aKer the initial assessment, and two
review authors (GD, JH) independently assessed these for inclusion
in the review. We resolved any disagreements between the two
authors by consulting a third review author (CM). We excluded
studies according to a hierarchy based on the inclusion criteria,
that is, wrong study design, wrong patient population, and wrong
comparator. We recorded the reason for study exclusion as the first
criterion not met, and we have presented our reasons for excluding
full-text reports in the Characteristics of excluded studies table. We
have produced a PRISMA flow chart (Figure 1) showing how we
selected our studies for inclusion in the review (Liberati 2009), along
with the reasons for study exclusion.
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Figure 1.   2 Study flow diagram.
 
Data extraction and management
Two review authors (CM, DE) independently extracted data from
included studies using a standard data extraction form that we
customised for use in this review. We pilot-tested the form. We
extracted the data detailed below.
1. Publication details.
2. Study eligibility criteria.
3. Study details (e.g. aim, study design, randomisation method,
study location, start and end dates).
4. Participant characteristics (e.g. number of participants, age, sex,
diagnostic criteria, study setting).
5. Description of intervention and comparator (e.g. duration
of treatment, timing, delivery, numbers of participants
randomised to groups).
6. Outcome data (e.g. numerical data such as means and standard
deviations, instruments used to assess outcomes of interest,
time points of outcome assessment, withdrawals).
7. Funding sources and any conflicts of interest for study authors.
We compared the extracted data and resolved any disagreements
by consensus or by deferment to a third review author (JH). One
review author (CM) input the data into Review Manager 5 (RevMan
2014), and a second review author (DE) checked these for accuracy.
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Assessment of risk of bias in included studies
Two review authors (CM, DE) independently assessed each
included study for risk of bias using the Cochrane tool for assessing
risk of bias, as outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We assessed risk of bias by
examining the following six domains.
1. Random sequence generation (checking for possible selection
bias): we assessed the method used to generate the allocation
sequence as being at low risk of bias (any truly random
process, e.g. random number table; computer random number
generator) or unclear risk of bias (method used to generate the
sequence not clearly stated). We excluded studies that used a
non-random process (e.g. odd or even date of birth; hospital or
clinic record number).
2. Allocation concealment (checking for possible selection
bias): we assessed the method used to conceal allocation
to interventions before assignment to determine whether
intervention allocation could have been foreseen in advance
of, or during, recruitment, or changed aKer assignment. We
assessed these methods as being at low risk of bias (e.g.
telephone or central randomisation; consecutively numbered
sealed opaque envelopes); unclear risk of bias (method not
clearly stated); or high risk of bias (e.g. open list).
3. Blinding of participants and personnel (checking for possible
performance bias): we assessed methods used to blind
study participants and personnel from knowledge of which
intervention a participant received. We assessed these methods
as being at low risk of bias (study states that it was blinded and
describes the method used to achieve blinding, such as identical
tablets matched in appearance or smell, or a double-dummy
technique) or unclear risk of bias (study states that it was blinded
but does not provide an adequate description of how this was
achieved). We considered studies that are not double-blind as
being at high risk of bias.
4. Blinding of outcome assessment (checking for possible
detection bias): we assessed methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed these methods
as being at low risk of bias (study has a clear statement that
outcome assessors were unaware of treatment allocation and
ideally describes how this was achieved) or unclear risk of bias
(study states that outcome assessors were blind to treatment
allocation but lacks a clear statement on how this was achieved).
We considered studies where outcome assessment was not
blinded as having high risk of bias.
5. Selective reporting (checking for reporting bias): we aimed
to assess whether reported primary and secondary outcome
measures were pre-specified in a protocol. If the trial protocol
was available from a trial registry, the reported outcomes should
be consistent with those listed in the protocol if the protocol
was registered before or at the time the trial began. We assessed
selective reporting as being at low risk of bias (studies reporting
primary and secondary outcomes as specified in the original
protocol) or high risk of bias (not all pre-specified outcomes
reported, or only for certain data collection time points).
6. Incomplete outcome data (checking for possible attrition bias
due to the quantity, nature, and handling of incomplete
outcome data): we assessed methods used to deal with
incomplete data as being at low risk (< 10% of participants
did not complete the study and/or used ‘baseline observation
carried forward’ analysis) or high risk of bias (used 'last
observation carried forward' analysis or 'completer' analysis).
We resolved disagreements by discussion or by deferment to a
third review author (JH). When information was missing from the
published papers, we contacted study authors. We have presented
our judgements in the 'Risk of bias' tables for each study, and
we have provided statements to justify our decisions, along with
appropriate quotes from reports or personal communications to
support our decisions. We have produced figures summarising the
risk of bias for all included studies.
Measures of treatment e=ect
Continuous data
We analysed these data based on mean, standard deviation (SD),
and numbers of participants assessed for both intervention and
comparison groups to calculate mean diEerence (MD) and 95%
confidence interval (CI). If more than one study measured the same
outcome using diEerent validated scales, we intended to calculate
a standardised mean diEerence (SMD), SD, and 95% CI. We aimed to
calculate SMD as the diEerence in mean outcomes between groups
divided by the pooled SD of both groups. We used change from
baseline scores for continuous data.
Dichotomous data
We analysed these data based on the numbers of events and the
numbers of participants assessed in intervention and comparison
groups. We intended to use these data to calculate the risk ratio (RR)
and 95% CI.
Unit of analysis issues
The unit of analysis is the study participant with PD. For studies
with more than two arms, we planned to include only arms that met
the inclusion criteria of the review. For studies including multiple
intervention groups of interest, we aimed to combine all arms for a
single pair-wise comparison (Higgins 2011).
Dealing with missing data
When data were missing, we intended to contact study authors
to obtain the missing data. We planned to make two attempts
to contact study authors, although this was not required. We
examined reports of studies with missing data, and, when possible,
we reported the reasons for missing data.
Assessment of heterogeneity
When we were able to undertake a meta-analysis, we aimed to
assess heterogeneity using the I2 statistic that is included in the
forest plot of a Cochrane Review. We planned to regard a level
of heterogeneity above 50% as substantial or high, as explained
in the Cochrane Handbook for Systematic Reviews of Interventions,
Section 9.5.2 (Higgins 2011). If heterogeneity existed, we planned
to examine study reports to identify possible reasons for it. If
we identified suEicient studies, we aimed to undertake subgroup
analysis according to possible identified reasons for heterogeneity.
Assessment of reporting biases
If we were able to pool 10 or more trials in a single analysis,
we planned to create and examine a funnel plot to explore
possible small-study and publication biases. We intended to test
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for asymmetry using Egger's test (Egger 1997). When protocols
were available, we compared outcomes reported in published trial
reports with those listed in trial protocols to assess reporting bias.
Data synthesis
When two or more studies reported the same outcome and were
suEiciently similar in terms of treatments and participants, we
planned to undertake meta-analyses using a fixed-eEect model.
We intended to report pooled eEect measures for dichotomous
outcomes using Mantel-Haenszel methods, and for continuous
outcomes, the inverse variance method. If we noted considerable
heterogeneity that could not readily be explained, we planned to
use a random-eEects model. When it was not possible to pool
findings from studies in a meta-analysis, we aimed to present
the results of each study and to provide a narrative synthesis of
findings. We performed statistical analysis using Review Manager 5
(RevMan 2014).
Subgroup analysis and investigation of heterogeneity
If suEicient data were available, we aimed to conduct the following
subgroup analyses.
1. Severity of PD: defined as severe, moderate, or mild as scored on
the UDPRS subscale Part III (Fahn 1987).
2. Clinical subtypes: tremor dominant, mixed, akinetic/rigid.
3. DiEerent dosages of GLP-1 receptor agonists.
4. DiEerent durations of treatment.
Sensitivity analysis
If we identified suEicient studies, we intended to repeat the
analyses while excluding studies at high risk of bias.
Quality of the evidence
Independently, two review authors (CM, DE) assessed the quality
of evidence for the three primary outcomes using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach (Schünemann 2013). We used methods and
recommendations as described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
To ensure consistency and reproducibility of GRADE judgements,
we assessed key outcomes using the criteria below for each of the
five domains.
1. Study limitations: if a study suEers from major limitations,
such as lack of blinding, these are likely to result in a biased
assessment of the intervention eEect.
2. Indirectness of evidence: this may occur when the review
intervention of interest is not compared directly with
comparators of interest, or when trials that meet the inclusion
criteria address a restricted version of the review question in
terms of participants, intervention, comparator, or outcomes.
3. Consistency of eEect: when studies show diEering estimates of
eEects, we must look for explanations for heterogeneity.
4. Imprecision of results: this occurs if included studies have few
participants or events and large confidence intervals.
5. Publication bias: this occurs if investigators do not report studies
- usually those with no eEect, or outcomes - typically harmful
ones or those showing no eEect.
The GRADE system uses the following criteria for assigning the
grade of evidence.
1. High: we are very confident that the true eEect lies close to that
of the estimate of the eEect.
2. Moderate: we are moderately confident in the eEect estimate;
the true eEect is likely to be close to the estimate of eEect, but
there is a possibility that it is substantially diEerent.
3. Low: our confidence in the eEect estimate is limited; the true
eEect may be substantially diEerent from the estimate of the
eEect.
4. Very low: we have very little confidence in the eEect estimate;
the true eEect is likely to be substantially diEerent from the
estimate of eEect.
We downgraded the GRADE rating by one (-1) or two (-2) levels if we
identified:
1. serious (-1) or very serious (-2) limitations to study quality;
2. important inconsistency (-1);
3. some (-1) or major (-2) uncertainty about directness;
4. imprecise or sparse data (-1); or
5. a high probability of reporting bias (-1).
We have provided reasons for our decisions regarding grading of the
quality of evidence.
'Summary of findings' tables
We created two ‘Summary of findings’ tables to summarise results
for the three primary outcomes (PD motor impairment, health-
related quality of life, and adverse events) for two comparisons.
For adverse events, we have presented separate data for serious
adverse events and weight loss. We have presented in these tables
our assessment of the quality of evidence. We used GRADEpro
soKware to prepare the tables (GRADEpro 2015), importing data
from Review Manager 5 (RevMan 2014).
R E S U L T S
Description of studies
Results of the search
Our searches yielded 99 unique records. AKer screening titles and
abstracts, we excluded 63 records and obtained the full text of the
remaining 23. We assessed these 23 full-text articles and excluded
five that we determined to be duplicates. Two studies met our
inclusion criteria and are described in 11 full-text articles. Seven
studies are ongoing (Characteristics of ongoing studies). See Figure
1 for a flowchart illustrating study selection.
Included studies
Two studies described in 11 papers are included in this review.
In both studies, participants received exenatide. One study
compared exenatide with placebo, with all participants continuing
to receive their usual treatment (Athauda 2017), and the other
study compared exenatide plus conventional treatment with
conventional treatment (Aviles-Olmos 2013b) (we have termed this
comparison group 'no treatment'). Athauda 2017 is described in
five papers. Three of these papers describe post-hoc analyses of
study data; thus their findings are not included in this review. Aviles-
Olmos 2013b is described in six papers. A total of 107 participants
GLP-1 receptor agonists for Parkinson's disease (Review)
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were randomised across the two studies, and there were three
dropouts. Both studies were conducted in the UK.
Methods
Although both were randomised, controlled, parallel-group
studies, one study was double-blind (Athauda 2017), and the other
was single-blind (Aviles-Olmos 2013b). In the single-blind study
(Aviles-Olmos 2013), study participants and investigators were
unblinded to the assigned intervention, but assessments of the
MDS-UPDRS subscale Part III were video recorded and rated by
clinicians who were blinded to randomisation. Both studies were
based both in a research institute and in tertiary care.
Participants
Eligible participants were at Hoehn and Yahr stage 2.5 or less
(Athauda 2017), or they were at Hoehn and Yahr stage 2 to 2.5
(Aviles-Olmos 2013b), when on medication (Hoehn 1967). Athauda
2017 recruited participants aged 25 to 75 years, and Aviles-Olmos
2013b recruited participants aged 45 to 70 years, with at least five
years of symptoms. The mean age of study participants was similar
in both studies, ranging from 57.8 years (control group) to 61.6 years
(intervention group) in Athauda 2017, and ranging from 59.4 years
(control group) to 61.4 years (intervention group) in Aviles-Olmos
2013b.
Intervention
In the double-blind study (Athauda 2017), participants were
taught how to self-administer weekly subcutaneous injections of
exenatide 2 mg or placebo for 48 weeks, in addition to their
usual medication. Participants were followed up at 60 weeks (i.e.
aKer a 12-week washout period). In the single-blind study (Aviles-
Olmos 2013b), participants in the intervention group were taught
how to self-administer twice-daily 5 µg exenatide injections for
one month, then twice-daily injections of 10 µg exenatide for
11 months (equivalent to a 0.14 mg weekly dose). Participants
in both intervention and control groups continued to receive
their conventional treatment. Participants were followed up at 14
months (i.e. aKer a 2-month washout period) (Aviles-Olmos 2013b),
and again at 24 months (i.e. aKer a 12-month absence of exenatide)
(Aviles-Olmos 2014).
Outcomes
The main outcome for both studies was PD motor impairment
measured by the MDS-UPDRS subscale Part III oE medication (i.e.
aKer withdrawal of levodopa overnight representing a period of
at least eight hours). For secondary outcomes, both studies also
assessed MDS-UPDRS Parts I, II, III, and IV, as well as PDQ-39, MATTIS
DRS, MADRS, and the Dyskinesia Rating Scale, in the on-medication
state. These outcomes were reported as mean change from
baseline. Studies also reported the numbers of adverse events,
including change in weight. Athauda 2017 assessed outcomes at
12, 24, 36, 48, and 60 weeks post baseline. Aviles-Olmos 2013b
assessed outcomes at 6, 12, 14, and 24 months post baseline.
Excluded studies
All five excluded studies were duplicates.
Risk of bias in included studies
We have provided details of the risk of bias for each study in the
Characteristics of included studies table. Figure 2 and Figure 3
present a summary of the risk of bias for both included studies.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Athauda 2017 + + + + + + +
Aviles-Olmos 2013 + + - + + + +
 
Allocation
We judged both studies to be at low risk of selection bias.
Athauda 2017 used a commercial company to generate the random
sequence and to allocate participants.
Blinding
In both studies, assessment of the primary outcome was
undertaken by assessors blinded to treatment groups. We judged
the single-blind study to be at high risk of performance bias (Aviles-
Olmos 2013). These investigators reported that participants might
detect their treatment allocation as a result of adverse events
including injection site reactions.
Incomplete outcome data
We assessed the two studies as being at low risk of attrition bias.
In Athauda 2017, 60 of the 62 randomised participants (97%) were
GLP-1 receptor agonists for Parkinson's disease (Review)









Cochrane Database of Systematic Reviews
included in the primary analysis, and in Aviles-Olmos 2013, 44 of
the 45 randomised participants (98%) were included in the analysis
Selective reporting
We judged both studies to be at low risk of selective reporting
bias. Both studies were prospectively registered with clinical trials
registries, and the outcomes they presented in their published
reports matched those stated in the registries.
Other potential sources of bias
We considered the two studies to be at low risk of other potential
biases. One study reported some imbalance between intervention
and control groups at baseline in terms of MDS-UPDRS Part III
scores, but these were adjusted for in the analysis.
E=ects of interventions
See: Summary of findings 1 GLP-1 receptor agonists compared to
placebo for adults with Parkinson's disease; Summary of findings
2 GLP-1 receptor agonists compared to no treatment for adults with
Parkinson's disease
As we were keen to assess the neuroprotective eEects of GLP-1
receptor agonists, in our analyses, we have used data from
outcomes assessed two to three months post cessation of
treatment, unless stated otherwise. We have presented narratively
the data from outcomes measured at a later follow-up.
GLP-1 receptor agonists versus placebo
One study with 60 participants included in primary analyses
contributed data to all the following outcomes in this comparison
(Athauda 2017). For the analyses, we used data from the 60 weeks
post baseline assessment (unless stated otherwise) following a 12-
week washout period.
Primary outcomes
1. MDS-UPDRS Part III
Data show a statistically significant diEerence in change from
baseline in MDS-UPDRS Part III oE-medication scores when groups
receiving exenatide were compared with those receiving placebo
(mean diEerence (MD) -3.10, 95% confidence interval (CI) -6.11 to
-0.09) (unadjusted) (Analysis 1.1). Participants receiving exenatide
reported a mean decrease in oE-medication scores representing
improvement in motor impairment. However, 3.10 did not exceed
the minimal clinically important diEerence (MCID) for improvement
in motor impairment of -3.25 (Horváth 2015). We rated the
quality of evidence as low. We downgraded the evidence once for
indirectness as the intervention consisted of only one receptor
agonist (RA), and once for imprecision due to a small sample
size. Athauda 2017 adjusted the mean diEerence in change from
baseline at 60 weeks for Hoehn and Yahr stage and baseline raw
MDS-UPDRS Part III scores (Hoehn 1967), revealing a diEerence of
-3.5 (95% CI -6.7 to -0.3). This value exceeds the MCID of -3.25 points
for detecting improvement (Horváth 2015).
2. Health-related quality of life
Data show no statistically significant diEerence in change from
baseline in HRQoL scores assessed by the PDQ-39 scale when
groups receiving exenatide were compared with those receiving
placebo (MD -1.80, 95% CI -6.95 to 3.35) (Analysis 1.2). The MD did
not exceed the MCID for improvement in HRQoL of -4.72 (Horváth
2017). Similarly, there was no statistically significant diEerence in
change from baseline in HRQoL scores as assessed by the EQ5D
scale when groups receiving exenatide were compared with those
receiving placebo (MD 0.07, 95% CI -0.03 to 0.16) (Analysis 1.3), or
by the EQ5D VAS (MD 5.00, 95% CI -3.42 to 13.42) (Analysis 1.4). We
rated the quality of evidence as low. We downgraded the evidence
once for indirectness as the intervention was only one RA, and once
for imprecision due to a small sample size and to the CI including
the null eEect and risk of appreciable harm and benefit.
3. Adverse events
Serious adverse events (SAEs)
Eight SAEs were reported (intervention (I) = 6, comparator (C) = 2).
"Significant weight loss" was reported as a single SAE in the placebo
group, but review authors considered that none of the SAEs were
related to the intervention; thus we have not included the data in a
meta-analysis. It is not clear whether adverse events were assessed
at 48 or 60 weeks.
Weight loss
Data show no statistically significant diEerence in the number
of participants reporting weight loss at 48 weeks when groups
receiving exenatide and those given placebo were compared (risk
ratio (RR) 1.25, 95% CI 0.89 to 1.76) (Analysis 1.5). We rated the
quality of evidence as low. We downgraded the evidence once for
indirectness as the intervention was only one RA, and once for
imprecision due to a small sample size and to the CI including the
null eEect and risk of appreciable harm and benefit. Study authors
reported that at 48 weeks, a total of 21 participants had lost less
than 2 kg (I = 11, C = 10), five participants had lost between 2 and
4 kg (I = 2, C = 3), and 16 participants had lost more than 4 kg (I =
11, C = 5). It is unclear whether any participants experienced rapid
weight loss.
Athauda 2017 reported that participants in the exenatide group lost
a mean of 2.6 kg (95% CI -4.0 to -1.2) compared to a mean weight
loss in the control group of 0.6 kg (95% CI -1.9 to 0.8) at 48 weeks.
However, study authors found no significant correlation between
degree of weight loss and change in score for the primary outcome.
Other adverse events
Participants reported a range of adverse events. Athauda 2017
reported these data as the number of events experienced
by individuals across all time points by group. In terms
of gastrointestinal adverse events, participants reported the
following.
1. Nausea: a total of 26 events (I = 16, C = 10).
2. Constipation: a total of 23 events (I = 12, C = 11).
3. Diarrhoea: a total of 14 events (I = 8, C = 6).
4. Abdominal pain: a total of 8 events (I = 5, C = 3).
5. Loss of appetite: a total of 4 events (I = 3, C = 1).
6. Vomiting: a total of 2 events (I = 2, C = 0).
Athauda 2017 reported that there was no statistically significant
correlation between the presence or absence of weight loss,
nausea, loss of appetite, or abdominal pain and treatment group
(χ2 = -0.388, P = 0.5330). Seven participants in the exenatide group
and 11 in the placebo group reported weight gain.
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Other adverse events reported by participants over all time points
included the following.
1. Injection site reaction: a total of 53 events (I = 27, C = 26).
2. Increased time oE medication: a total of 20 events (I = 8, C = 12).
Secondary outcomes
1. PD motor impairment assessed by a validated scale other than o=
medication MDS-UPDRS Part III
There was no statistically significant diEerence in change from
baseline in MDS-UPDRS Part III scores on medication when groups
receiving exenatide were compared with those receiving placebo
(MD 0.52, 95% CI -2.34 to 3.38) (Analysis 1.6). Similarly, there was
no statistically significant diEerence in change from baseline in
UDysRS scores when groups receiving exenatide were compared
with those receiving placebo (MD -0.90, 95% CI -4.29 to 2.49)
(Analysis 1.7).
2. Non-motor outcomes
Data show no statistically significant diEerences in change from
baseline in MDS-UPDRS Part I scores (MD -1.20, 95% CI -3.23 to 0.83)
(Analysis 1.8) or NMSQuest scores (MD -0.80, 95% CI -10.83 to 9.23)
(Analysis 1.9) when groups receiving exenatide were compared with
those receiving placebo.
3. Activities of daily living
Data show no statistically significant diEerence in change from
baseline in MDS-UPDRS Part II scores when groups receiving
exenatide were compared with those receiving placebo (MD -1.00,
95% CI -3.04 to 1.04) (Analysis 1.10).
4. Psychological outcomes
There was no statistically significant diEerence in change from
baseline in Mattis DRS scores (MD 1.50, 95% CI -0.40 to 3.40)
(Analysis 1.11) or MADRS scores (MD -0.70, 95% CI -2.41 to 1.01)
(Analysis 1.12) when groups receiving exenatide were compared
with those receiving placebo.
Subgroup analysis and sensitivity analysis
Data were insuEicient for subgroup analyses or sensitivity analyses
to be conducted for this comparison.
GLP-1 receptor agonists versus no treatment
One study with 44 participants included in the primary analyses
contributed data to all the following outcomes in this comparison
(Aviles-Olmos 2013). In the analyses, we used data from the 14
months post baseline assessment following a two-month washout.
We also report narratively data from 24 months post baseline.
Primary outcomes
1. MDS-UPDRS Part III
At 14 months, data show a statistically significant diEerence
in change from baseline in MDS-UPDRS Part III oE-medication
scores when groups receiving exenatide were compared with
those receiving no treatment (MD -4.50, 95% CI -8.64 to -0.36)
(Analysis 2.1). This value exceeds the MCID of -3.25 points for
detecting improvement (Horváth 2015). We rated the quality of
evidence as very low. We downgraded the evidence by one level for
study limitations of unclear risk of selection bias and high risk of
performance bias; we downgraded by one level for indirectness as
the intervention was only one RA; and we downgraded by one level
for imprecision due to a small sample size.
Study authors report that when scores from the open-label rating of
rigidity scores were added to the blinded data, an MD of 7.2 points
(95% CI 2.1 to 12.2; P = 0.006) was obtained, with participants in
the exenatide group showing a mean improvement of 0.8 points
(standard deviation (SD) 8.7) and those in the no treatment group
showing a mean decline of 6.4 points (SD 7.8).
At 24 months, study authors report a statistically significant
diEerence in change from baseline in MDS-UPDRS Part III oE-
medication scores measured blindly when groups receiving
exenatide were compared with those receiving no treatment (MD
5.6, 95% CI 2.2 to 9.0; P = 0.002). Participants in the exenatide group
showed a mean improvement of 1.1 points (SD 5.9), and those
receiving no treatment showed a mean decline of 4.5 points (SD
5.3). Study authors report that when scores from the open-label
rating of rigidity scores were added to the blinded data, an MD of 8.0
points (95% CI 3.8 to 12.2; P < 0.001) was obtained, with participants
in the exenatide group showing a mean decline of 0.5 points (SD
7.3) and those in the no treatment group showing a mean decline
of 8.5 points (SD 6.3).
2. Health-related quality of life
At 14 months, there was no statistically significant diEerence in
change from baseline in HRQoL scores assessed by the PDQ-39 SI
when groups receiving no treatment were compared with those
receiving placebo (MD 3.50, 95% CI -2.75 to 9.75) (Analysis 2.2). We
rated the quality of evidence as very low. We downgraded evidence
by one level for study limitations of unclear risk of selection bias
and high risk of performance bias; we downgraded by one level
for indirectness as the intervention was only one RA; and we
downgraded by one level for imprecision due to a small sample and
the CI including the null eEect and risk of appreciable harm and
benefit.
At 24 months, study authors reported that there was a non-
significant diEerence in scores from baseline when the two groups
were compared. Participants receiving exenatide showed a mean
diEerence from baseline on the PDQ-39 SI of -0.1 points (SD 12.3,
95% CI -5.9 to 5.6), and participants receiving no treatment reported
a mean diEerence of 1.2 points (SD 9.3, 95% CI -2.7 to 5.1; P = 0.682).
3. Adverse events
A total of four SAEs were reported in both groups - by four
participants in the exenatide group and by three in the no treatment
group. These events included sciatica, insomnia, possible transient
ischaemic attack, prostatectomy, lymph node dissection, anxiety,
and fractured radius. There was no significant diEerence in the
number of all-cause SAEs reported by those receiving exenatide
compared to those receiving no treatment (RR 1.60, 95% CI 0.40 to
6.32) (Analysis 2.3). We rated the quality of evidence as very low.
We downgraded the evidence by one level for study limitations of
unclear risk of selection bias and high risk of performance bias; we
downgraded by one level for indirectness as the intervention was
only one RA; and we downgraded by one level for imprecision due
to a small sample and the CI including the null eEect and risk of
appreciable harm and benefit.
GLP-1 receptor agonists for Parkinson's disease (Review)









Cochrane Database of Systematic Reviews
Aviles-Olmos 2013 presents the total number of adverse events
reported at 1, 3, and 9 months. Participants reported a range of
adverse events. In terms of the total number of gastrointestinal
adverse events, participants reported the following.
1. Nausea: a total of 21 events (I = 13, C = 8).
2. Constipation: a total of 32 events (I = 18, C = 14).
3. Diarrhoea: a total of 12 events (I = 7, C = 5).
4. Abdominal pain: a total of 12 events (I = 6, C = 6).
5. Loss of appetite: a total of 5 events (I = 5, C = 0).
6. Weight loss: a total of 27 events (I = 19, C = 8).
Other adverse events reported by participants included the
following.
1. Injection site bruising: I = 2.
2. Increased time oE medication: a total of 16 events (I = 4, C = 12).
There was a statistically significant diEerence in change from
baseline in weight measured in kg when groups receiving exenatide
were compared with those receiving no treatment (MD -2.40, 95% CI
-4.56 to -0.24) (Analysis 2.4). We rated the quality of evidence as very
low. We downgraded the evidence by one level for study limitations
of unclear risk of selection bias and high risk of performance bias;
we downgraded by one level for indirectness as the intervention
was only one RA; and we downgraded by one level for imprecision
due to a small sample and the CI including the null eEect and risk
of appreciable harm and benefit. Details are insuEicient to show
whether any participants experienced rapid weight loss.
At 24 months, study authors reported a non-significant between-
group diEerence in weight loss from baseline of 0.1 kg (95% CI 3.0
to 2.8; P = 0.93), with participants receiving exenatide experiencing
a mean weight loss from baseline of 1.6 kg (SD 3.1) and participants
receiving no treatment experiencing a mean wight loss of 1.7 kg (SD
5.8).
Secondary outcomes
1. PD motor impairment as assessed by a validated scale other than o=
medication MDS-UPDRS Part III
Data show a significant diEerence in change from baseline in MDS-
UPDRS Part III scores on medication when receiving exenatide
were compared with those receiving no treatment (MD -9.80, 95%
CI -14.47 to -5.13) (Analysis 2.5). This value exceeds the MCID
of -3.25 points for detecting improvement (Horváth 2015). There
was no significant diEerence in change from baseline in Rush
Dyskinesia Rating Scale scores when groups receiving exenatide
were compared with those receiving no treatment (MD 0.90, 95% CI
-1.49 to 3.29) (Analysis 2.6).
At 24 months, study authors reported that participants receiving
exenatide reported a mean diEerence from baseline in MDS-UPDRS
Part III scores on medication of -0.9 points (SD 6.9, 95% CI -4.2
to 2.3), and control participants reported a mean diEerence of
7.8 points (SD 6.7, 95% CI 5.0 to 10.7), representing a significant
diEerence (P < 0.001).
At 24 months, participants receiving exenatide reported a mean
diEerence from baseline in Rush Dyskinesia Rating Scale scores on
medication of 0.8 points (SD 6.0, 95% CI -2.0 to 3.6), and control
participants reported a mean diEerence of -0.6 points (SD 3.0, 95%
CI -1.8 to 0.7), representing a non-significant diEerence (P = 0.328).
2. Non-motor outcomes
There was no significant diEerence in change from baseline in
MDS-UPDRS Part I scores when groups receiving exenatide were
compared with those receiving no treatment (MD -3.70, 95% CI -7.45
to 0.05) (Analysis 2.7).
At 24 months, participants receiving exenatide reported a mean
diEerence from baseline in MDS-UPDRS Part I scores of 2.0 points
(SD 4.2, 95% CI 0.0 to 4.0), and participants receiving no treatment
reported a mean diEerence of 5.1 points (SD 5.5, 95% CI 2.8 to 7.4),
representing a significant diEerence (P = 0.049).
Data on NMSQuest scores were not published for 14 months (Aviles-
Olmos 2013b). At 24 months, participants receiving exenatide
reported a mean diEerence from baseline in NMSQuest scores of
-0.8 points (SD 3.8, 95% CI -2.6 to 1.0), and control participants
reported a mean diEerence of 0.2 points (SD 4.3, 95% CI -1.6 to 2.1),
representing a non-significant diEerence (P = 0.403).
3. Activities of daily living
There was no statistically significant diEerence in change from
baseline in MDS-UPDRS Part II scores when groups receiving
exenatide were compared with those receiving no treatment (MD
-2.90, 95% CI -6.41 to 0.61) (Analysis 2.8).
At 24 months, participants receiving exenatide reported a mean
diEerence from baseline in MDS-UPDRS Part II scores of 2.7 points
(SD 5.4, 95% CI 0.2 to 5.3), and control participants reported a mean
diEerence of 7.0 points (SD 5.0, 95% CI 4.9 to 9.1), representing a
significant diEerence (P = 0.009).
4. Psychological outcomes
Data show a significant diEerence in change from baseline in Mattis
DRS scores when groups receiving exenatide were compared with
those receiving no treatment (MD 6.30, 95% CI 2.79 to 9.81) (Analysis
2.9). There was no statistically significant diEerence in change from
baseline in MADRS scores (MD -2.20, 95% CI -5.40 to 1.00) (Analysis
2.10) when groups receiving exenatide were compared with those
receiving no treatment.
At 24 months, participants receiving exenatide reported a mean
diEerence from baseline in Mattis DRS scores of 1.8 points (SD
6.5, 95% CI -1.2 to 4.8), and control participants reported a mean
diEerence of -3.5 points (SD 6.4, 95% CI -0.8 to -6.3), representing a
significant mean diEerence between groups (P = 0.006).
At 24 months, participants receiving exenatide reported a mean
diEerence from baseline in MADRS scores of -1.9 points (SD 5.2, 95%
CI 0.5 to -4.3), and control participants reported a mean diEerence
of 1.5 points (SD 7.0, 95% CI -1.4 to 4.4), representing a non-
significant diEerence (P = 0.79).
Subgroup analysis and sensitivity analysis
We had insuEicient data to undertake subgroup analyses or
sensitivity analyses for this comparison.
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D I S C U S S I O N
Summary of main results
Two studies are included in this review evaluating the eEectiveness
and safety of glucagon-like peptide-1 (GLP-1) receptor agonists
(RAs) for Parkinson's disease (PD). One study of data from 60
participants compared a GLP-1 RA (exenatide) with placebo, and
one study of data from 44 participants compared a GLP-1 RA
(exenatide) with no treatment (both groups continued to receive
their usual medication). Seven studies are ongoing, assessing the
eEects of exenatide, liraglutide, lixisenatide and semaglutide.
GLP-1 receptor agonists versus placebo
Outcomes were assessed at 60 weeks (i.e. aKer a 12-week washout
period following 48 weeks of intervention). In terms of primary
outcomes, findings show there was significant improvement at 60
weeks in motor impairment assessed by the Movement Disorder
Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Part III in the oE-medication state for participants receiving
exenatide compared to those receiving placebo. The mean
diEerence is below that of a minimal clinically important diEerence
(MCID) of -3.25 points for detecting improvement (Horváth 2015);
however, the adjusted mean diEerence of -3.5 points exceeded an
MCID. The quality of the evidence was rated as low. There was no
diEerence between groups in terms of health-related quality of life
(HRQoL) or the number of participants reporting weight loss; we
rated the quality of evidence for these outcomes as low.
In terms of secondary outcomes, exenatide did not provide
any improvement in motor impairment as assessed by MDS-
UPDRS Part III scores in the on-medication state, nor in
Unified Dyskinesia Rating Scale (UDysRS) scores. There was
no improvement among participants receiving exenatide for
non-motor outcomes as assessed by MDS-UPDRS Part I and
the Non-Motor Symptoms Questionnaire (NMSQuest). Similarly,
participants receiving exenatide showed no improvement in
activities of daily living as assessed by MDS-UPDRS Part II, nor
in psychological outcomes as assessed by the Mattis Dementia
Rating Scale (DRS) or the Montgomery-Åsberg Depression Rating
Scale (MADRS), when compared to participants receiving placebo.
Adjusted mean diEerence scores were not significantly diEerent
between the two groups.
GLP-1 receptor agonists versus no treatment
Outcomes were assessed at 14 months (60.8 weeks) (i.e. aKer a two-
month washout period following 12 months of intervention) and
at 24 months. In terms of primary outcomes, findings show there
was significant improvement at 14 months in motor impairment
assessed by MDS-UPDRS Part III in the oE-medication state for
participants receiving exenatide compared to those receiving no
treatment. The mean diEerence is above that of an MCID of -3.25
points for detecting improvement (Horváth 2015). The quality of
evidence was rated as very low. There was no diEerence between
groups in terms of HRQoL; the quality of this evidence was rated as
very low. Participants receiving exenatide were significantly more
likely to report weight loss (quality of evidence was rated as very
low); however, there was no significant diEerence in the number
of participants reporting serious adverse events (SAEs) (quality of
evidence was rated as very low).
In terms of secondary outcomes, there was significant
improvement in motor impairment as assessed by MDS-UPDRS Part
III in the on-medication state for participants receiving exenatide
compared to those receiving no treatment. The mean diEerence is
above that of an MCID of -3.25 points for detecting improvement
(Horváth 2015). However, there was no significant diEerence in
motor impairment as measured by the Rush Dyskinesia Rating
Scale. Similarly there was no significant change in non-motor
outcomes as assessed by MDS-UPDRS Part I scores, activities of
daily living as measured by MDS-UPDRS Part II, or psychological
outcomes as assessed by the MADRS.
At 24 months post baseline (i.e. 12 months post cessation
of exenatide), study participants receiving exenatide scored
significantly lower MDS-UPDRS Part III scores oE medication than
participants receiving no treatment. There was no diEerence
between groups in terms of HRQoL or weight loss. In terms
of secondary outcomes, there was a significant between-group
diEerence in MDS-UPDRS Part III scores as assessed, but there was
no diEerence in Rush Dyskinesia Rating Scale scores. For non-motor
impairment, there was a significant between-group diEerence as
assessed by MDS-UPDRS Part I but not by NMSQuest. There was a
significant between-group diEerence for activities of daily living as
assessed by MDS-UPDRS Part II. There was a significant between-
group diEerence for psychological outcomes as assessed by the
Mattis DRS but not by the MADRS.
Evidence of improvement in motor and non-motor scores on the
MDS-UPDRS following a minimum washout period of three months
suggests that exenatide may slow progression of the disease. It
is diEicult to draw conclusions regarding a symptomatic eEect of
exenatide, as studies were designed to measure long-term rather
than short-term eEects of exenatide. To assess symptomatic eEects
of a GLP-1 RA would require outcomes to be assessed several times
immediately aKer the start of the intervention.
Overall completeness and applicability of evidence
We found only two studies that met our inclusion criteria; they
compared the eEects of administering exenatide versus placebo
and no treatment. Although it was not possible to pool data
from these studies, there were similarities within the studies.
Participants in both studies self-administered exenatide for similar
lengths of time, and the primary outcome for both studies was
motor impairment as assessed by MDS-UPDRS Part III while oE
medication and following a washout period. Improvements in
assessments of PD disability using the MDS-UPDRS have been
reported among study participants receiving placebo (Goetz 2000).
Both included studies assessed HRQoL, adverse events, non-motor
impairment, psychological impairment, and eEects on activities of
daily living. Although the sample size of these studies was small,
attrition was low. Both studies reported some imbalance in baseline
characteristics between intervention and control groups, including
slight diEerences in disease duration and severity. One study
undertook a pre-specified adjustment in analyses to account for
this imbalance. Another study was designed as a single-blind study,
with study authors reporting that this was due to the prohibitive
costs of developing a placebo. This study was thus considered as a
proof-of-concept study that would provide the opportunity to test
whether findings in the laboratory could be replicated in people
with PD. Both studies were single-centre studies. Both studies
collected data at multiple time points, but in our analyses, we used
data collected at similar time points to increase the comparability
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of our analyses. One study did not report between-group mean
diEerences in score changes for some outcomes.
Quality of the evidence
According to GRADE criteria, we rated the certainty of evidence from
Athauda 2017 as low, and from Aviles-Olmos 2013 as very low. We
rated Athauda 2017 at low risk for all biases. Aviles-Olmos 2013
was designed as a proof-of-concept study. We judged this study
to be at high risk of performance bias. In this study, participants
self-administered exenatide using a pen, and as the costs to
produce a placebo pen were considered by study authors to be
prohibitive, it was not possible to blind participants and personnel
to treatment groups. The primary outcome for this study and
many of the secondary outcomes assessed were rated by assessors
blinded to treatment groups; thus we rated detection bias as
low. We downgraded Aviles-Olmos 2013 for study limitations.
We downgraded both studies for indirectness, as this review is
concerned with assessing the eEectiveness of any RA, and both
studies examined the eEects of just one RA - exenatide; thus our
findings relate only to exenatide. We downgraded both studies
for imprecision, with confidence intervals for some outcomes
including the possibility of opposite eEects.
Potential biases in the review process
We undertook a comprehensive search for relevant studies,
including handsearching of conference abstracts. We followed the
systematic review process as outlined by the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). Two review
authors undertook each stage of the review process, thereby
reducing the risk of introducing bias into the study selection
process. We are confident that we have identified all relevant
randomised controlled trials.
Agreements and disagreements with other studies or
reviews
One recent systematic review assessing the neuroprotective role
of GLP-1 RAs concluded that their use for longer than three to six
months led to improvement in motor symptoms of people with
PD, while control groups experienced deterioration in symptoms
(Erbil 2019). Much of the work done so far on GLP-1 RAs has been
undertaken in the laboratory with rodents.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found low- or very low-certainty evidence suggesting that
the GLP-1 RA exenatide improves motor impairment as assessed
by MDS-UPDRS Part III in the oE-medication state following a
minimum of 11 months of medication and a maximum washout
period of 12 weeks. As improvement in motor impairment was
seen at three months post cessation of exenatide, this suggests
that exenatide may have a disease-modifying eEect on PD. No
conclusions can be drawn about the symptomatic benefits of
exenatide. We are uncertain whether exenatide improved HRQoL
as assessed by the Parkinson's Disease Questionnaire Summary
Index (PDQ-39 SI). We found low- or very low-certainty evidence
suggesting that for people taking exenatide, there may be little or
no diEerence in the number of SAEs. We found low- or very low-
certainty evidence suggesting that exenatide may lead to slight
weight loss. The findings of our review are most applicable to adults
with mild PD less than stage 2.5 as assessed by the Hoehn and Yahr
Scale (Hoehn 1967).
Implications for research
We found only two studies for inclusion in this review, and of
these, one was a single-blind study. Both studies had small sample
sizes and some baseline imbalances between intervention and
control groups. Studies with larger sample sizes would be less
likely to show an imbalance in baseline characteristics. Both studies
assessed eEects of the intervention on the same primary and
similar secondary outcomes. In addition, both studies used similar
intervention and washout periods. Findings from future double-
blind, placebo-controlled, multi-centre trials adopting a similar
protocol as the two included studies would contribute additional
evidence to this review. Long-term follow-up of participants to
establish longer-term eEects of the intervention is encouraged,
while taking account of the progressive nature of PD. Both studies
assessed the impact of exenatide; therefore studies of other GLP-1
RAs are needed.
Seven ongoing studies are assessing the eEects of exenatide,
liraglutide, lixisenatide and semaglutide. Findings from these
studies can be included in an update of this review. Novel dual
GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs
also show neuroprotective eEects in PD models (Hölscher 2018).
Further clinical trials using newer drugs of this class are likely to be
conducted in due course.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: randomised, double-blind, placebo-controlled, parallel-group study
Duration of study: participants were followed up at 60 weeks
Number of centres: 1
Location: London, UK
Study setting: research/tertiary care facility
Withdrawals: 2 participants before 12 weeks (I = 1, C = 1), both excluded from analysis
Discontinued treatment: 3 participants (I = 1, C = 2). All continued follow-up assessments as per proto-
col
Compliance: assessed as "very high: 58 patients reported not missing a single dose"
Dates of study: June 2014 to August 2016 (from ClinicalTrials.gov; https://clinicaltrials.gov/ct2/show/
NCT01971242)
Participants Number of participants: 62 randomised, 2 withdrawals, so 60 included in analysis (I = 31, C = 29)
Age in years, mean (SD): intervention: 61.6 (8.2), control: 57.8 (8.0)
Gender, N (%): intervention: female 9 (29%), male 22 (71%); control: female 7 (24%), male 22 (76%)
Duration of diagnosis at baseline, years (SD): intervention: 6.4 (3.3); control: 6.4 (3.3)
Severity of condition, N (%):
Hoehn and Yahr stage 1.0 to 2.0: intervention: 29 (94%); control: 29 (100%)
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Hoehn and Yahr stage 2.5: intervention: 2 (6%); control: 0 (0%)
Study inclusion criteria:
• Men and women
• Aged 25 to 75 years
• Idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria
• On dopaminergic treatment with wearing-oE effects
• Judged able to administer the trial drug or to arrange carer administration of the trial drug
• At Hoehn and Yahr stage 2.5 or less when on treatment
Study exclusion criteria:
• Diagnosis or suspicion of other cause for parkinsonism (i.e. patients with clinical features indicating a
diagnosis of progressive supranuclear palsy, multiple systems atrophy, drug-induced parkinsonism,
dystonic tremor, or essential tremor), lack of DaTSCAN appearance consistent with diagnosis of PD
• Body mass index < 18.5
• Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial
protocol/DaTSCAN acquisition
• Concurrent dementia defined by a score < 120 on the Mattis Dementia Rating Scale
• Concurrent severe depression defined by a score > 16 on the MADRS
• Prior intracerebral surgical intervention for Parkinson’s disease
• Already actively participating in a trial of a device, drug, or surgical treatment for Parkinson’s disease
• Previous exposure to exenatide
• Type 1 or type 2 diabetes mellitus
• Severely impaired renal function with creatinine clearance < 30 mL/min
• Hyperlipidaemia
• History of pancreatitis
• Severe gastrointestinal disease (e.g. gastroparesis)
• History or suspicion of thyroid cancer
• Known or suspected intolerance of DaTSCAN or potassium iodide administration
• Female who is pregnant or breastfeeding
• Individuals who lack the capacity to give informed consent
• Any medical or psychiatric condition that in the investigator’s opinion compromises the ability of the
potential participant to participate
Interventions Intervention: self-administered exenatide 2 mg via subcutaneous injection once weekly for 48 weeks +
regular drugs
Comparator: self-administered placebo via subcutaneous injection once weekly for 48 weeks + regular
drugs
Outcomes Primary: MDS-UPDRS part III scores in the practically defined oE-medication state at 60 weeks
Secondary: differences at 48 and 60 weeks between groups for:
• each subsection of MDS-UPDRS (on medication);
• scores on the Unified Dyskinesia Rating Scale, the Montgomery and Åsberg Depression Rating Scale,
the Non-Motor Symptoms Severity Scale, the Parkinson’s Disease 39-item Quality of Life Question-
naire, and the Mattis Dementia Rating Scale (on medication);
• dopamine transporter availability as measured by DaTSCAN;
• 13 timed motor tests in both oE-medication and on-medication states;
• levodopa equivalent dose; and
• 3-day Hauser diary of Parkinson’s disease state
Notes Funding: Michael J Fox Foundation for Parkinson Disease
Athauda 2017  (Continued)
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Interests: AJL reports grants from the Frances and Renee Hock Fund, consulting fees from Britannia
Pharmaceuticals (Genus) and BIAL Portela, and honoraria from Profile Pharma, Teva, Lundbeck, BIAL,
Roche, Britannia, UCB, Nordiclnfu Care, NeuroDerm, and Decision Resources
TTW has received honoraria from Britannia Pharmaceuticals
PL has received honoraria from Medtronic and St Jude Medical
NHG is a named inventor on a National Institutes of Health patent describing the use of GLP-1 RAs in
neurodegenerative disorders
TF has received honoraria from Profile Pharma, BIAL, AbbVie, Genus, Medtronic, and St Jude Medical
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “We used SealedEnvelope, an independent, commercial, Internet-based ran-
domisation service that generated the online randomisation list on the basis
of guidance from the trial IT manager (SH) and trial statistician (SSS)”
Allocation concealment
(selection bias)
Low risk "SealedEnvelope will provide a unique trial identification code for each re-
cruited participant. ……At the baseline visit, the clinical investigator will enter
the patient’s initials, gender, date of birth, date of consent, criteria fulfilment,
and PD severity strata into the SealedEnvelope.com secure website, which will
then allocate the appropriate trial identification code to the patient…… All






Low risk "SealedEnvelope will provide the patient trial identification codes at randomi-
sation. The trial drug kit identification code list will be prepared by the Trial
Statistician and provided separately to SealedEnvelope and to the QP, who
will ensure that labelling of trial drug packs occurs appropriately and so as to
ensure complete blinding of the IMP to all investigators, participants, and the
pharmacy staE on the study"
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Triple blinding of investigators, participants, and pharmacy staE
"To prevent the possibility of adverse events compromising rater blinding, all
adverse events, biochemical results, blood pressure, heart rate, and weight





Low risk Attrition rate was low (< 5%) and balanced between groups
Selective reporting (re-
porting bias)
Low risk None was identified
Other bias Low risk None was identified. Some baseline imbalances were noted (i.e. MDS-UPDRS





Methods Study design: randomised, single-blind, controlled, parallel-group study
Aviles-Olmos 2013 
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Duration of study: participants were followed up at 14 and 24 months
Number of centres: 1
Location: London, UK
Study setting: research/tertiary care facility
Withdrawals: 1 participant before 3 months (I = 1), excluded from analysis
Discontinued treatment: 3 participants (I = 2, C = 1). All continued follow-up assessments at 12
months. Data were missing from 2 at 14 months (I = 1, C = 1)
Compliance: judged "to be very high for all participants"
Date of study: July 2010 to March 2013 (from ClinicalTrials.gov; https://clinicaltrials.gov/ct2/show/
NCT01174810)
Participants Number of participants: 45 randomised, 1 withdrawal, so 44 included in analysis (intervention = 20,
control = 24)
Age in years, mean (SD): intervention: 61.4 (6.0); control: 59.4 (8.4)
Gender N (%): intervention: female 5 (25%), male 15 (75%); control: female 4 (17%), male 20 (83%)
Duration of symptoms at baseline, years (SD): intervention: 9.6 (3.4); control: 11.0 (5.9)
Severity of condition, N (%): Hoehn and Yahr stage 2:2.5 (intervention: 14:6, control: 16:8)
Study inclusion criteria:
• Male or female. Female patients had to be postmenopausal (defined as 12 months of spontaneous
amenorrhoea, or 6 months of spontaneous amenorrhoea, with FSH levels > 40 mIU/mL), surgically
sterilised (post hysterectomy and/or oophorectomy). Male patients with female partners who have
child-bearing potential must use adequate contraception (condoms ± spermicidal gel/foam) through-
out the duration of the trial period
• Aged 45 to 70 years
• Diagnosis of idiopathic Parkinson’s disease of moderate severity - equivalent to Hoehn and Yahr stage
2 to 2.5 - in the "on-medication" state (bilateral symptoms but still physically independent)
• Disease onset after 40 years of age
• Disease duration > 5 years
• On L-dopa treatment. Patient must be on oral L-dopa treatment - with or without dopamine agonist
including apomorphine, MAO-B inhibitor, COMT inhibitor, amantadine, beta-blocker, anticholinergic
treatment
• History of wearing-oE phenomenon - duration of action of single dose of L-dopa < 6 hours
• Stable PD medication for preceding 3 months (i.e. no change in medication type or dose)
• UPDRS motor oE-medication score > 15
• L-dopa responsiveness, defined as > 33% improvement in UPDRS motor oE-medication score follow-
ing L-dopa challenge
• Able to give informed consent
• Able to comply with trial protocol and willing to attend necessary clinic visits oE medication
Study exclusion criteria:
• Diagnosis or suspicion of other cause for parkinsonism including vascular parkinsonism, post-trau-
matic parkinsonism, drug- or toxin-induced parkinsonism, or other neurodegenerative condition in-
cluding multiple system atrophy, progressive supranuclear palsy, Huntington’s disease, Wilson’s dis-
ease, pantothenate kinase neurodegeneration (PKAN), Alzheimer’s disease, Creutzfeld-Jacob disease
• Known abnormality on CT or MRI brain imaging considered to be causing symptoms or signs of neu-
rological dysfunction, or considered likely to compromise compliance with trial protocol
• Concurrent dementia defined by a score < 120 on the Mattis Dementia Rating Scale
Aviles-Olmos 2013  (Continued)
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• Concurrent severe depression defined as a score > 16 on the MADRS
• Exposure to neuroleptic drugs within 6 months before baseline assessment
• Prior intracerebral surgical intervention for Parkinson’s disease including deep brain stimulation, le-
sional surgery, growth factor administration, gene therapy, or cell transplant
• Already actively participating in a trial of a device, drug, or surgical treatment for Parkinson’s disease,
or trial participation within previous 30 days
• Type 1 diabetes mellitus
• Type 2 diabetes mellitus on insulin treatment
• End-stage renal disease or severely impaired renal function with creatinine clearance < 30 mL/min
• History of severe cardiac disease (angina, myocardial infarction, or cardiac surgery in preceding 2
years)
• History of pancreatitis
• History of alcoholism
• Severe gastrointestinal disease including gastroparesis
• Ongoing treatment with sulphonylurea
• Female who is pregnant or breastfeeding or of child-bearing potential
Interventions Intervention: self-administered, twice-daily exenatide added to conventional PD treatment. Partic-
ipants were supplied with a 5 μg exenatide pen device (Byetta 5 μg) for 1 month, then were supplied
with a 10 μg exenatide pen device (Byetta 10 μg) for the subsequent 11 months
Comparator: continued to receive conventional PD treatment
Outcomes Primary: blinded video rating of MDS-UPDRS Part III in the practically defined oE-medication condi-
tion; change from baseline to 12, 14, and 24 months
Secondary: differences between groups in change from baseline to 12, 14, and 24 months on:
• each subsection of the MDS-UPDRS (on medication);
• timed motor tests;
• levodopa equivalent dose;
• scores on the Dyskinesia Rating Scale, the Montgomery and Åsberg Depression Rating Scale, the
Parkinson’s Disease 39-item Quality of Life Questionnaire, the Mattis Dementia Rating Scale-2, EQ-5D,
and NMSQuest;
• SCOPA Sleep Scale;
• SCOPA AUT Scale;
• smell Identification test;
• DAT (SPECT) scan appearances; and
• safety assessments including measurements of vital signs and weight, electrocardiography, labora-
tory blood tests, and recording of adverse events
Notes Funding: The Cure Parkinson’s Trust
Interests: T. Foltynie is supported by the Parkinson's Appeal. He has received consultancies from Abbie
Pharmaceuticals. He holds grants from the Michael J Fox Foundation and the Brain Research Trust and
European Union FP7. He has received payment for lectures including service on speakers’ bureaus from
St Jude Medical, Medtronic, Genus Pharmaceuticals, and Novartis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The randomisation list was computer generated by a senior statistician... us-
ing 2 strata according to patient PD severity" (Foltynie 2020 [pers comm])
Allocation concealment
(selection bias)
Low risk "The randomisation list generated was kept by the trial pharmacist securely
and completely separately from the trial team. She had no knowledge of which
Aviles-Olmos 2013  (Continued)
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participants were attending, but notified the randomisation outcome to the
team on request after the participants baseline visit was completed, and dis-





High risk “In view of the prohibitive costs associated with manufacture of (QP released)
placebo versions of the exenatide pens, these were not available for the pur-
poses of this trial, which was necessarily configured to be open-label from the
patient’s perspective”
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Outcome assessors were blinded to treatment groups. For the primary out-
come, "assessments of PD severity using MDS-UPDRS part III were made 'oE-
medication' after an overnight period and were video recorded to allow objec-
tive rating of PD disability by observers blinded to randomisation outcomes.




Low risk Attrition was low (< 10%) and was balanced between groups
Selective reporting (re-
porting bias)
Low risk The pre-specified primary outcome and most secondary outcomes were re-
ported







DaTSCAN: DAT binding as assessed by [123I]FP-CIT single-photon emission computed tomography.
EQ-5D: EuroQol scale measuring health status in five dimensions.
FSH: follicle-stimulating hormone.
I: intervention.
MADRS: Montgomery-Åsberg Depression Rating Scale.
MAO-B: monoamine oxidase-B.
MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
MRI: magnetic resonance imaging.
NMSQuest: Non-Motor Symptoms Questionnaire.
PD: Parkinson's disease.
SCOPA: Scales for Outcomes in Parkinson's Disease.
SD: standard deviation.
SPECT: single-photon emission computed tomography.
UPDRS: Unified Parkinson's Disease Rating Scale.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety,
and tolerability of 36 weeks of treatment with NLY01 in early-stage Parkinson’s disease
Methods Multi-centre, randomised, double-blind, placebo-controlled study
Participants With early PD
Interventions Intervention treatment 1: NLY01 exenatide and polyethylene glycol (PEG) 2.5mg injection for 36
weeks
Clinicaltrials.gov identifier: NCT04154072 
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Intervention treatment 2: NLY01 exenatide and polyethylene glycol (PEG) 5.0mg injection for 36
weeks
Comparison: Placebo
Outcomes Change in Unified Parkinson's Disease Rating Scale in combined score of Parts II and III from base-
line






Study name Effects of exenatide on motor function and the brain
Methods Multi-centre, randomised, double-blind, placebo-controlled, parallel comparison, phase IIa clinical
study
Participants Early stages of PD
Interventions Intervention treatment 1: PT320 2.0mg injected subcutaneously once a week for 48 weeks
Intervention treatment 2: PT320 2.5mg injected subcutaneously every two weeks for 48 weeks.
(patients will be injected PT320 2.5 mg and placebo alternately once a week.)
Comparison: placebo injected subcutaneously once a week for 48 weeks
Outcomes Change of MDS-UPDRS (Movement Disorder Society -Unified Parkinson's Disease Rating Scale )
part 3 score from baseline






Study name A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson’s dis-
ease
Methods Single-centre, double-blind, placebo-controlled study
Participants Early stages of PD
Interventions Intervention: liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg for 52 weeks
Comparison: placebo once daily for 52 weeks
Outcomes Change in the motor (Part III) Movement Disorders Society-Unified Parkinson Disease Rating Scale
(MDS-UPDRS) score
Clinicaltrials.gov identifier: NCT02953665 
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Study name Study to evaluate the effect of lixisenatide in patients with Parkinson's disease (LixiPark)
Methods Multi-centre, randomised, placebo-controlled, double-blind, parallel-arm proof-of-concept trial
Participants With early PD
Interventions Intervention: lixisenatide (10 μg/d for 14 days, then 20 μg/d), once daily subcutaneously
Comparator: placebo, once-daily subcutaneous injection
Outcomes Change from baseline to end point (M12) in MDS-UPDRS III motor examination score, evaluated in
the best ON condition in patients with early Parkinson's disease






Study name Effect of GLP1R stimulation on neuroprotection and inflammation in Parkinson's disease
Methods Single-centre, double-blind, placebo-controlled study
Participants Newly diagnosed patients with PD, age 40 to 75
Interventions Intervention: semaglutide subcutaneous, 1.0 mg weekly, 48 months
Comparator: placebo for 4 months, then semaglutide for 24 months
Outcomes MDS-UPDRS Part III in OFF-medication state
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Study name Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's dis-
ease (Exenatide-PD3)
Methods Randomised, double-blind, parallel-group, placebo-controlled, phase 3 trial
Participants Newly diagnosed patients
Interventions Intervention: Exenatide extended release 2mg (Bydureon) once weekly for 96 weeks
Comparison: Placebo once weekly for 96 weeks
Outcomes MDS-UPDRS part 3 motor sub-score in the practically defined OFF medication






Study name Effect of exenatide on disease progression in early Parkinson’s disease
Methods Single-centre, double-blind, placebo-controlled study
Participants Early stages of PD
Interventions Intervention: exenatide 2mg once weekly for 18 months
Comparison: placebo once weekly for 18 months
Outcomes Primary: FDG-PET analysis
Secondary: MDS-UPDRS part 3 in OFF medication state




GLP1R: glucagon-like peptide-1 receptor.
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Comparison 1.   Exenatide vs placebo (60 weeks post-baseline)





Statistical method Effect size
1.1 PD motor impairment - MDS-UP-
DRS Part III (oE medication)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.2 HRQoL - PDQ-39 SI 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.3 HRQoL - EQ5D 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.4 HRQoL - EQ5D-VAS 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.5 Adverse events - weight loss (kg)
(assessed at 48 weeks post baseline)
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.6 PD motor impairment - MDS-UP-
DRS Part III
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.7 PD motor impairment - UDysRS 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.8 Non-motor impairment - MDS-UP-
DRS Part I
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.9 Non-motor impairment -
NMSQuest
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.10 Activities of daily living - MDS-
UPDRS Part II
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.11 Psychological outcomes - Mattis
DRS
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.12 Psychological outcomes - MADRS 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
 
 
Analysis 1.1.   Comparison 1: Exenatide vs placebo (60 weeks post-baseline),
Outcome 1: PD motor impairment - MDS-UPDRS Part III (o= medication)
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
-3.10 [-6.11 , -0.09]
Mean Difference
IV, Fixed, 95% CI
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Analysis 1.2.   Comparison 1: Exenatide vs placebo (60 weeks post-baseline), Outcome 2: HRQoL - PDQ-39 SI
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
-1.80 [-6.95 , 3.35]
Mean Difference
IV, Fixed, 95% CI




Analysis 1.3.   Comparison 1: Exenatide vs placebo (60 weeks post-baseline), Outcome 3: HRQoL - EQ5D
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
0.07 [-0.03 , 0.16]
Mean Difference
IV, Fixed, 95% CI




Analysis 1.4.   Comparison 1: Exenatide vs placebo (60 weeks post-baseline), Outcome 4: HRQoL - EQ5D-VAS
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
5.00 [-3.42 , 13.42]
Mean Difference
IV, Fixed, 95% CI




Analysis 1.5.   Comparison 1: Exenatide vs placebo (60 weeks post-baseline),
Outcome 5: Adverse events - weight loss (kg) (assessed at 48 weeks post baseline)
Study or Subgroup
Athauda 2017












M-H, Fixed, 95% CI
1.25 [0.89 , 1.76]
Risk Ratio
M-H, Fixed, 95% CI




Analysis 1.6.   Comparison 1: Exenatide vs placebo (60 weeks post-
baseline), Outcome 6: PD motor impairment - MDS-UPDRS Part III
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
0.52 [-2.34 , 3.38]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Exenatide Placebo
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Analysis 1.7.   Comparison 1: Exenatide vs placebo (60 weeks
post-baseline), Outcome 7: PD motor impairment - UDysRS
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
-0.90 [-4.29 , 2.49]
Mean Difference
IV, Fixed, 95% CI




Analysis 1.8.   Comparison 1: Exenatide vs placebo (60 weeks post-
baseline), Outcome 8: Non-motor impairment - MDS-UPDRS Part I
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
-1.20 [-3.23 , 0.83]
Mean Difference
IV, Fixed, 95% CI




Analysis 1.9.   Comparison 1: Exenatide vs placebo (60 weeks
post-baseline), Outcome 9: Non-motor impairment - NMSQuest
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
-0.80 [-10.83 , 9.23]
Mean Difference
IV, Fixed, 95% CI




Analysis 1.10.   Comparison 1: Exenatide vs placebo (60 weeks post-
baseline), Outcome 10: Activities of daily living - MDS-UPDRS Part II
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
-1.00 [-3.04 , 1.04]
Mean Difference
IV, Fixed, 95% CI
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Analysis 1.11.   Comparison 1: Exenatide vs placebo (60 weeks post-
baseline), Outcome 11: Psychological outcomes - Mattis DRS
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
1.50 [-0.40 , 3.40]
Mean Difference
IV, Fixed, 95% CI




Analysis 1.12.   Comparison 1: Exenatide vs placebo (60 weeks
post-baseline), Outcome 12: Psychological outcomes - MADRS
Study or Subgroup
Athauda 2017
















IV, Fixed, 95% CI
-0.70 [-2.41 , 1.01]
Mean Difference
IV, Fixed, 95% CI




Comparison 2.   Exenatide vs no treatment (14 months (60.8 weeks) post baseline)





Statistical method Effect size
2.1 PD motor impairment - MDS-UPDRS
Part III (oE medication)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.2 HRQoL - PDQ-39 SI 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.3 Serious adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.4 Adverse events - weight loss (kg) (as-
sessed at 12 months (52 weeks))
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.5 PD motor impairment - MDS-UPDRS
Part III
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.6 PD motor impairment - Rush Dyskine-
sia Rating Scale
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.7 Non-motor impairment - MDS-UPDRS
Part I
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.8 Activities of daily living - MDS-UPDRS
Part II
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.9 Psychological outcomes - Mattis DRS 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.10 Psychological outcomes - MADRS 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Analysis 2.1.   Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post
baseline), Outcome 1: PD motor impairment - MDS-UPDRS Part III (o= medication)
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
-4.50 [-8.64 , -0.36]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.2.   Comparison 2: Exenatide vs no treatment (14
months (60.8 weeks) post baseline), Outcome 2: HRQoL - PDQ-39 SI
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
3.50 [-2.75 , 9.75]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.3.   Comparison 2: Exenatide vs no treatment (14 months
(60.8 weeks) post baseline), Outcome 3: Serious adverse events
Study or Subgroup
Aviles-Olmos 2013












M-H, Fixed, 95% CI
1.60 [0.40 , 6.32]
Risk Ratio
M-H, Fixed, 95% CI




Analysis 2.4.   Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post
baseline), Outcome 4: Adverse events - weight loss (kg) (assessed at 12 months (52 weeks))
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
-2.40 [-4.56 , -0.24]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours exenatide Favours no treatment
 
 
GLP-1 receptor agonists for Parkinson's disease (Review)









Cochrane Database of Systematic Reviews
Analysis 2.5.   Comparison 2: Exenatide vs no treatment (14 months (60.8
weeks) post baseline), Outcome 5: PD motor impairment - MDS-UPDRS Part III
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
-9.80 [-14.47 , -5.13]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.6.   Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks)
post baseline), Outcome 6: PD motor impairment - Rush Dyskinesia Rating Scale
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
0.90 [-1.49 , 3.29]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.7.   Comparison 2: Exenatide vs no treatment (14 months (60.8
weeks) post baseline), Outcome 7: Non-motor impairment - MDS-UPDRS Part I
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
-3.70 [-7.45 , 0.05]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.8.   Comparison 2: Exenatide vs no treatment (14 months (60.8
weeks) post baseline), Outcome 8: Activities of daily living - MDS-UPDRS Part II
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
-2.90 [-6.41 , 0.61]
Mean Difference
IV, Fixed, 95% CI
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Analysis 2.9.   Comparison 2: Exenatide vs no treatment (14 months (60.8
weeks) post baseline), Outcome 9: Psychological outcomes - Mattis DRS
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
6.30 [2.79 , 9.81]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.10.   Comparison 2: Exenatide vs no treatment (14 months (60.8
weeks) post baseline), Outcome 10: Psychological outcomes - MADRS
Study or Subgroup
Aviles-Olmos 2013
















IV, Fixed, 95% CI
-2.20 [-5.40 , 1.00]
Mean Difference
IV, Fixed, 95% CI




A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 Parkinson Disease:TI,AB,KY
#2 Parkinson*:TI,AB,KY
#3 #1 OR #2
#4 MESH DESCRIPTOR Glucagon-Like Peptide 1 EXPLODE ALL TREES WITH QUALIFIERS AA,AG
#5 ((glucagon like peptide* or GLP 1 or GLP1) ADJ3 (analog* or agonist*)):TI,AB,KY
#6 (exenatide or AC 2993 or ITCA 650):TI,AB,KY
#7 (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170):TI,AB,KY
#8 (albiglutide or GSK 716155):TI,AB,KY
#9 (elsiglutide):TI,AB,KY
#10 (lixisenatide or AVE 0010):TI,AB,KY
#11 (dulaglutide or LY2189265 or LY 2189265):TI,AB,KY
#12 (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031):TI,AB,KY
#13 (semaglutide or NN 9535 or NN9535):TI,AB,KY
#14 (teduglutide or ALX 0600 or ALX0600):TI,AB,KY
#15 OR/#4-#14
#16 #3 and #15 in Trials
Appendix 2. MEDLINE search strategy
#1 randomized controlled trial.pt.
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#2 controlled clinical trial.pt.
#3 randomized.ab.
#4 placebo.ab.
#5 clinical trials as topic.sh.
#6 randomly.ab.
#7 trial.ti.
#8 1 or 2 or 3 or 4 or 5 or 6 or 7
#9 animals.mh. not humans.mh.
#10 #8 not #9
#11 Parkinson Disease.mh.
#12 Parkinson*.ti,ab.
#13 #11 or #12
#14 exp Glucagon-Like Peptide 1/aa,ag [Analogs & Derivatives, Agonists]
#15 ((glucagon like peptide* or GLP 1 or GLP1) adj3 (analog* or agonist*)).tw.
#16 (exenatide or AC 2993 or ITCA 650).tw.
#17 (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170).tw.
#18 (albiglutide or GSK 716155).tw.
#19 (elsiglutide).tw.
#20 (lixisenatide or AVE 0010).tw.
#21 (dulaglutide or LY2189265 or LY 2189265).tw.
#22 (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031).tw.
#23 (semaglutide or NN 9535 or NN9535).tw.
#24 (teduglutide or ALX 0600 or ALX0600).tw.
#25 OR/14-24
#26 #10 and #13 and #25





#5 1 or 2 or 3 or 4
#6 Parkinson*.ti,ab.
#7 Parkinson Disease/exp
#8 6 or 7
#9 ((glucagon like peptide* or GLP 1 or GLP1) adj3 (analog* or agonist*)).tw.
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#10 (exenatide or AC 2993 or ITCA 650).tw.
#11 (liraglutide or NN 2211 or NN2211 or NNC 90 1170 or NNC90 1170).tw.
#12 (albiglutide or GSK 716155).tw.
#13 (elsiglutide).tw.
#14 (lixisenatide or AVE 0010).tw.
#15 (dulaglutide or LY2189265 or LY 2189265).tw.
#16 (taspoglutide or BIM 51077 or BIM51077 or ITM 077 or ITM077 or R 1583 or R1583 or RO 5073031 or RO5073031).tw.
#17 (semaglutide or NN 9535 or NN9535).tw.
#18 (teduglutide or ALX 0600 or ALX0600).tw.
#19 or/9-37
#20 5 and 8 and 19
H I S T O R Y
Protocol first published: Issue 3, 2018
Review first published: Issue 7, 2020
C O N T R I B U T I O N S   O F   A U T H O R S
The idea for this review was conceived by all review authors. The protocol was draKed by all review authors.








S O U R C E S   O F   S U P P O R T
Internal sources
• Internal sources of support, Other
No support was received to write this protocol.
External sources
• External sources of support, Other
No support was received to write this protocol.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. To clarify the interventions and comparators that we would include in this review, we added the sentence, "We included studies in
which experimental and comparator groups received an intervention (either active or inactive) in addition to conventional treatment"
to the Types of interventions section.
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2. We modified our definition of weight loss as an adverse event to "Adverse events, including rapid weight loss (> 1.5 kg/week)". We
modified our definition of serious adverse events to "we have defined adverse events as serious based on information reported by
individual trials".
3. As we were keen to assess the neuroprotective eEects of GLP-1 RAs, we planned to report outcomes assessed two to three months post
cessation of treatment rather than immediately following cessation of treatment as initially planned.
4. We had planned to assess adverse events as "the number of participants with an adverse event associated with the intervention".
However, included studies reported the total number of adverse events reported by individuals over all time points.
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